SCHEMBL24539680

SCHEMBL24539680

CC(C)(c1cc(O)c(C(=O)Nc2ccccc2)c(O)c1)C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.44
ATM Q13315 1/20 0.43
GLA P06280 1/20 0.43
EPHX2 P34913 2/20 0.43
EPHX1 P07099 2/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NR1H4 Q96RI1 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
KCNK9 Q9NPC2 2/20 0.42
KCNK3 O14649 1/20 0.42
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
MAPK14 Q16539 1/20 0.41
POLB P06746 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24539677 0.83 GRM5 (0.46) RAB9AMEN1LMNAKMT2AKDM4E
SCHEMBL29627410 0.83 GRM5 (0.46) RAB9AMEN1LMNAKMT2AKDM4E
SCHEMBL29627401 0.73 RAB9A (0.50) HPGDRAB9ASMN1; SMN2KCNK9KCNK3
SCHEMBL14803027 0.71 EPHX2 (0.57) HPGDATMGLAEPHX2EPHX1
SCHEMBL846064 0.70 KEAP1 (0.48) ATMTSHRMAPT
SCHEMBL24539687 0.70 CNR1 (0.49) EPHX1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL29627397 0.69 NPC1 (0.50) RAB9ASMN1; SMN2RXFP1MEN1LMNA
SCHEMBL8737173 0.69 HPGD (0.50) HPGDATMGLAEPHX2EPHX1
SCHEMBL9806566 0.69 MEN1 (0.66) HPGDEPHX2EPHX1SMN1; SMN2KCNK9
SCHEMBL846603 0.69 TRPV1 (0.71) RAB9ASMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612358-B2 Resorcinol-based compounds and uses thereof SUTTER BAY HOSPITALS (US) 2026-04-28 US disclosed
US-20240059646-A1 RESORCINOL-BASED COMPOUNDS AND USES THEREOF ORGANIX INC. 2024-02-22 US disclosed
WO-2022133058-A1 RESORCINOL-BASED COMPOUNDS AND USES THEREOF SUTTER BAY HOSPITALS (US) 2022-06-23 WO disclosed
WO-2022133058-A1 RESORCINOL-BASED COMPOUNDS AND USES THEREOF SUTTER BAY HOSPITALS (US) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612358-B2 Resorcinol-based compounds and uses thereof CARM1, MALT1, RCOR1 HPGD 2185/4885ATM 4326/4885GLA 2239/4885
US-20240059646-A1 RESORCINOL-BASED COMPOUNDS AND USES THEREOF VHL, NQO1, HRAS HPGD 521/4885ATM 2448/4885GLA 2388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.